May 6, 2020 / 1:28 PM / 21 days ago

BRIEF-Amgen Announces Positive Top-Line Results From Otezla® Phase 3 Advance Study In Mild-To-Moderate Plaque Psoriasis

May 6 (Reuters) - Amgen Inc:

* AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM OTEZLA® (APREMILAST) PHASE 3 ADVANCE STUDY IN MILD-TO-MODERATE PLAQUE PSORIASIS

* AMGEN INC - STUDY SHOWED THAT ORAL OTEZLA 30 MG TWICE DAILY ACHIEVED A STATISTICALLY SIGNIFICANT IMPROVEMENT, COMPARED WITH PLACEBO

* AMGEN INC - ADVERSE EVENTS OBSERVED IN THIS TRIAL WERE CONSISTENT WITH KNOWN SAFETY PROFILE OF OTEZLA

* AMGEN INC - OTEZLA TREATMENT RESULTED IN SIGNIFICANT IMPROVEMENTS IN MEASURES OF MILD-TO-MODERATE PSORIASIS COMPARED WITH PLACEBO Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below